Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)

NCT06242691 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL: MK-1200
DRUG: Antiemetic

Sponsor

Merck Sharp & Dohme LLC